BACKGROUND: Organ confined prostate cancer (PCa) can be cured by radical retropubic prostatectomy (RRP); however, some tumors will still recur. Current tools fail to identify patients at risk of recurrence. Glutathione-S-transferases (GSTs) are involved in the metabolism of carcinogens, hormones and drugs. Thus, genetic polymorphisms that modify the GST activities may modify the risk of PCa recurrence. METHODS: We retrospectively recruited Argentine PCa patients treated with RRP to study the association between GST polymorphisms and PCa biochemical relapse after RRP. We genotyped germline DNA in 105 patients for: GSTP1 c.313A4G (p.105 Ile4Val, rs1695) by PCR-RFLP; and GSTT1 null and GSTM1 null polymorphisms by multiplex PCR. Kaplan-Meier curves and Cox proportional hazard models were used to evaluate these associations. RESULTS: Patients with GSTP1 c.313GG genotype showed shorter biochemical relapse-free survival (BRFS) (P ¼ 0.003) and higher risk for recurrence in unadjusted (Hazard ratio (HR) ¼ 3.16, 95% confidence interval (95% CI) ¼ 1.41-7.06, P ¼ 0.005) and multivariate models (HR ¼ 3.01, 95% CI ¼ 1.13-8.02, P ¼ 0.028). We did not find significant associations for GSTT1 and GSTM1 genotypes. In addition, we found shorter BRFS (P ¼ 0.010) and increased risk for recurrence for patients having two or more risk alleles when we combined the genotypes of the three GSTs in multivariate models (HR ¼ 3.06, 95% CI ¼ 1.20-7.80, P ¼ 0.019). CONCLUSIONS: Our results give support to the implementation of GSTs genotyping for personalized therapies as a novel alternative for PCa management for patients who undergo RRP. To the best of our knowledge, this is the first study that examined GST polymorphisms in PCa progression in Argentine men. Replication of our findings in larger cohort is warranted.
INTRODUCTION
Prostate cancer (PCa) is the second most common type of cancer diagnosed in men and the sixth leading cause of cancer-related deaths worldwide. However, the incidence and mortality rates are highly variable between countries and ethnicities. 1 In Argentina, PCa is the most frequent type of cancer and the second cause of death from cancer among Argentine men (http:// www.msal.gov.ar/inc/equipos_analisis.php 2 ). Early detection of PCa has resulted in more men being diagnosed with localized disease. Surgical resection of the entire gland, radical retropubic prostatectomy (RRP), is one therapeutic option with curative purposes for men with organ confined PCa. However, 30-40% of patients will have a biochemical relapse after RRP, which may indicate clinical recurrence of aggressive disease. Current clinical indicators of PCa recurrence and mortality after RRP have limited sensitivity and specificity. [3] [4] [5] Thus, the ability to establish the risk of progression after surgery is of high importance for patient management and to avoid overtreatment.
The glutathione-S-transferases (GSTs) are phase II enzymes involved in detoxification of reactive oxygen species, environmental carcinogens, metabolism of steroid hormones and metabolism of chemotherapeutic agents. 6 Different GST isoforms have diverse, but overlapping, substrate specificities and have been shown to be highly expressed in the prostate. 7 Genetic polymorphisms that alter the activity of GSTs may affect the level of hormones and xenobiotics within the prostate which, in turn, may alter the risk of PCa development and progression.
Several studies have been conducted to determine the role of GST polymorphisms as risk factors for PCa development; 8, 9 but only few sought to analyze the effect of these polymorphisms on PCa progression, with inconclusive results. [10] [11] [12] In addition, most studies that analyzed GST polymorphisms have been carried out in Caucasians, few in African-Americans and Asians, and only two were conducted in Hispanics to evaluate the effect of these polymorphisms on the risk PCa development. 13, 14 Therefore, the role of GSTs in PCa in the Hispanic population is understudied.
To the best of our knowledge, this study is the first to analyze genetic polymorphisms in Hispanic PCa patients from Argentina and to evaluate their effect of these variations on PCa progression. We examined the GSTT1 null, GSTM1 null and GSTP1 c.313A4G (p.105 Ile4Val) polymorphisms and their potential association with PCa biochemical relapse in a retrospective cohort of Argentine men who underwent RRP.
MATERIALS AND METHODS Patients
We designed a hospital-based case-case study to determine the association between GST polymorphisms and PCa biochemical relapse after RRP. We retrospectively recruited 105 patients histologically diagnosed with PCa from August 2008 to November 2010 at the Hospital de Clıńicas José de San Martıń, Buenos Aires, Argentina. All patients underwent RRP as their primary therapeutic strategy (date of RRP from December 1998 to July 2010). Patient recruitment, follow-up and maintenance of updated medical records were performed by trained urologists and oncologists. All patients were Argentine citizens, and by definition Hispanics. Most of them had predominant Caucasian ancestry, although as reported for this population, some admixture of Amerindian and African ancestry is to be expected. 15 The study protocol was approved by the Institutional Ethical Committee and followed the Ethical Principles enunciated by the Declaration of Helsinki. All patients who agreed to participate in the study signed a written informed consent.
Genotyping
Germline DNA was extracted from peripheral blood. We genotyped three polymorphisms in three GST genes: GSTP1 c.313A4G (NM_000852.3:c.313A4G; p.105 Ile4Val; rs1695), GSTT1 null and GSTM1 null. The genotyping of GSTP1 c.313A4G was performed by PCR-RFLP assay. GSTT1 null and GSTM1 null genotypes were assessed by multiplex PCR. This method allowed us to discriminate the null genotype (homozygote deletion), determined by the absence of band in the electrophoresis, from the heterozygote and homozygote present genotypes. We called the null genotype when there was an absence of a band for either GSTT1 or GSTM1 with at least one band for one of the two genes being present (internal PCR control). Samples that did not amplify for both genes were repeated twice or three times to discard a PCR failure. These samples were called null for both GSTT1 and GSTM1 only when the following criteria were met: (i) all replications were concordant, (ii) other samples within the same PCR using the same PCR mix amplified (reaction control) and (iii) PCRs for double-null samples showed the specific amplicon for other genes (DNA quality control). Details of methods are available online in Supplementary information SI1. Genotyping call rates were 98% for GSTP1, 99% for GSTT1 and 98% for GSTM1. All PCRs were performed in a DNA Enginet Thermocycler (Bio-Rad, Hercules, CA, USA). PCRs and digested products were analyzed by 2% agarose (Genbiotech SRL, Buenos Aires, Argentina) gel electrophoresis in 1 Â TAE buffer (0.8 M Tris; 0.4 M sodium acetate; 0.04 M EDTA; pH 8.3) and dyed with ethidium bromide (Promega, Madison, WI, USA). Gels were photographed and analyzed with the G-Box system (Syngene, Frederick, MD, USA) and the Genesnap software (Syngene). Samples that failed were repeated once or twice as needed. Genotyping outputs were read by two independent laboratory members, and 10-12% of blindly random selected samples were re-analyzed as quality control of the experiments. The results were considered for the final analyses when there was 100% agreement between the two independent readers, and when there was a 100% concordance between samples and blinded repeats.
Statistical analysis
Biochemical relapse was defined as a rise in serum PSA of 40.2 ng ml À 1 after RRP. Univariate and multivariate analyses were conducted using Cox proportional hazard models to study the association between polymorphisms and PCa biochemical relapse and to estimate hazard ratios (HRs) and 95% confidence intervals (95% CIs). Multivariate models included margin involvement of the resected prostate, pathologic Gleason score, pathologic T stage, serum PSA level at diagnosis, family history of PCa in first-degree relatives, smoking status and age at diagnosis as covariates. Smoking status was stratified as follows: (i) never smokers: patients that never smoke, (ii) former smokers: patients that quit smoking at least 1 year prior PCa diagnosis and (iii) current smokers: patients that smoke at the time of PCa diagnosis or patients that quit smoking no 41 year prior PCa diagnosis. To study biochemical relapse-free survival (BRFS), time was calculated from date of RRP to date of biochemical relapse or last followup. Kaplan-Meier plots were used to evaluate the association between clinical variables or genotypes and biochemical relapse, and the comparison between groups was done using the log-rank test.
All statistical analyses were carried out using Stata/SE 11.2 (StataCorp. 2009, Stata Statistical Software: Release 11, College Station, TX, USA).
RESULTS
The clinico-pathological characteristics of the studied patients are shown in Table 1 . Twelve (11.4%) patients were diagnosed with PCa with normal serum PSA levels (p4 ng ml À 1 ). Nearly half presented with a Gleason score of o7, and 66% of patients with a combined Gleason score of X7 showed a 7(3 þ 4) score. Most resected prostates showed tumor-free margins (77.5%) and 50.5% of patients were diagnosed with pT2-stage tumors. One-third of patients developed a relapse during follow-up. The median followup time for patients without relapse was 84 months , and 36 months (3-132) for patients who recurred.
Association analyses between clinico-pathological variables and biochemical relapse Kaplan-Meier curves were used to study BRFS across Gleason score categories, pathologic T stage and margin involvement of the resected prostate, which are known risk factors for biochemical relapse. Gleason score was evaluated using the following categories: p6, 7 (3 þ 4), 7 (4 þ 3) and X8 (Figure 1a) . Considering that the survival curve of patients with a Gleason score of 7 (3 þ 4) is similar to the curve of patients with a score of p6, we combined these two groups into a low-risk Gleason score. We also combined the Gleason scores 7 (4 þ 3) and X8 into a high-risk Gleason score. Analysis of the dichotomized Gleason score showed a statistically significant difference in BRFS ( Figure 1b ) and was associated with a nearly 2. 16 We found that high-risk patients (PSA420 ng ml À 1 , stage pT3 or Gleason score X8; stratification according to D'Amico et al. 3 ) with tumor-positive margins had shorter BRFS (log-rank P ¼ 0.026, data not shown). However, we observed no association with the other two groups, which might be due to small numbers.
Overall, the studied patients followed the current clinical criteria used to evaluate PCa biochemical relapse risk.
Analyses of genotypes and risk of biochemical relapse Figure 2 shows one agarose gel electrophoresis for the multiplex PCR. The genotypes distributions are shown in Table 2 , and were similar to those reported for Caucasians and US Hispanics.
We found that carriers of the null genotypes had slightly shorter BRFS than carriers of the non-null genotypes, albeit these differences were not statistically significant (Figures 3a and b for  GSTT1 and GSTM1, respectively) . Non-statistically significant associations were found between these polymorphisms and biochemical relapse risk in the unadjusted and multivariate Cox models (Table 3 ; Supplementary information SI2). Figure 4 shows one agarose gel electrophoresis for the enzymatic digestion of the GSTP1 amplicon. The genotype distribution and allelic frequencies are shown in Table 2 , and were similar to those reported for the Caucasian and US Hispanic populations.
For the analysis of the GSTP1 (Figure 3c ). Given that we did not observe meaningful differences between survival of patients with the GSTP1 c.313 AA and c.313 AG genotypes, we considered a recessive model in which a modification of the enzymatic activity and phenotype is only obtainable when two G alleles are present. We found that homozygote G patients had shorter BRFS when compared with patients with the AA or AG combined genotypes ( Figure 3d ) and was associated with a threefold higher risk for recurrence in the unadjusted model (Table 3 ). This association Figure 1 . Biochemical relapse-free survival (BRFS) analysis by different clinico-pathological characteristics. To study BRFS, time was calculated from date of radical retropubic prostatectomy to date of biochemical relapse or last follow-up. The figure depicts the Kaplan-Meier survival analysis by: (a) Gleason score (log-rank P ¼ 0.016), (b) dichotomous Gleason score (log-rank P ¼ 0.011), (c) pathological T stage (log-rank P ¼ 0.024) and (d) margin status (log-rank Po0.001).
remained statistically significant when the model was further adjusted for margin status, Gleason score, pT stage, PSA level at diagnosis, family history of PCa, smoking status and age at diagnosis (Table 3 ; Supplementary information SI2). The estimates did not significantly change when further adjusting for GSTT1 and GSTM1 genotypes (Supplementary information SI2).
Because GSTs are enzymes that typically participate in the same metabolism pathways with overlapping substrate specificity, we considered an additive combined score that captures information on the genotypes of the three GSTs. We stratified the genotypes as follows: 0-risk-allele genotype (GSTT1 present, GSTM1 present and GSTP1 c.313 AA þ AG), 1-risk-allele genotype (GSTT1 null, GSTM1 present and GSTP1 c.313 AA þ AG; or GSTT1 present, GSTM1 null and GSTP1 c.313 AA þ AG; or GSTT1 present, GSTM1 present and GSTP1 c.313 GG), 2-risk-allele genotype (GSTT1 null, GSTM1 null and GSTP1 c.313 AA þ AG; or GSTT1 null, GSTM1 present and GSTP1 c.313 GG; or GSTT1 present, GSTM1 null and GSTP1 c.313 GG) and 3-risk-allele genotype (GSTT1 null, GSTM1 null and GSTP1 c.313 GG). The genotype distribution is shown in Table 2 . Only one patient presented the 3-risk-allele genotype; therefore, he was pooled with the 2-risk-allele group. We found that patients who carried two or more (2 þ ) GST risk alleles had shorter BRFS compared with patients with 0 or 1 risk allele (Figure 3e ). The unadjusted proportional hazard model showed that patients with 2 þ risk alleles had a nearly threefold increased risk for biochemical relapse compared with patients with 0 risk alleles (Table 3 ). This association remained statistically significant after adjustment for other potential risk factors in multivariate models (Table 3 ; Supplementary information SI2).
DISCUSSION
The clinical course of localized PCa is difficult to predict given that men with similar tumor features can experience strikingly diverse outcomes. Clinicians face the struggle of efficiently identifying high-risk patients given the limited accuracy of currently available staging tools for defining patients at risk of progression to lethal disease. We believe our study is the first study conducted among Argentine patients to examine the association between GST polymorphisms and the risk of PCa biochemical relapse. We found that GSTP1 c.313 A4G polymorphism and the combined genotype of three GSTs are associated with the risk of recurrence and the time to recurrence in Argentine men with localized PCa.
Whereas many studies have investigated the role of GST polymorphisms as risk factors for PCa development, 8, 9, 13, 14 fewer have analyzed the potential role of these polymorphisms on PCa recurrence, progression and PCa-specific death. [10] [11] [12] In particular, none of these studies were conducted among Hispanics. Agalliu et al. 11 found an increased risk for PCa-specific mortality among Caucasians who have the GSTM1 null genotype after adjustment for potential confounders (HR ¼ 3.76, 95% CI ¼ 1.59-8.91); however, the small number of PCa-specific deaths limited the power of the study. No associations with recurrence and disease progression were found. 11 Another study failed to find a statistically significant increased risk for recurrence in Caucasian men for individual polymorphisms (GSTT1 null, GSTM1 null and GSTP1 c.313 A4G) and for the combined genotypes. 10 However, an increased risk for biochemical relapse was found for the GSTM1 null genotype among patients with high-grade (Gleason score X8) or high-stage (stage XT3a) tumors. 10 In our patient cohort, we had few men with Gleason score X8; therefore, we were unable to do analyses among high-grade patients. However, overall, our findings are in agreement with the published data given that we found a positive non-significant association between the GSTM1 and GSTT1 null genotypes and risk for recurrence and shorter BRFS. This lack of significance might be partly due to the modest number of patients enrolled in our study. Figure 2 . Agarose gel electrophoresis of the multiplex PCR for GSTT1 and GSTM1 genotyping. The figure depicts an example of one 2% agarose gel electrophoresis dyed with ethidium bromide used to determine the GSTT1 and GSTM1 genotypes by multiplex PCR. Lanes 1, 3, 7, 8 and 9: GSTT1 present/GSTM1 null; lane 2: GSTT1 null/GSTM1 null; lanes 4, 5, 6 and 10: GSTT1 present/GSTM1 present; lane 11: GSTT1 null/GSTM1 present; M: 100 bp marker (Productos Bio-Ló gicos, Buenos Aires, Argentina). Samples that did not amplify for both genes were repeated twice or three times to discard a PCR failure. Hispanic from Chile genotype frequency ranges reported by Acevedo et al. 13 and Caceres et al.
The GSTP1 c.313 A4G (p.105 Ile4Val) SNP alters the substrate specificity, activity and thermostability of the GSTpi enzyme. 17 Our results also showed that the GSTP1 c.313 A4G (p.105 Ile4Val) SNP is associated with the risk of biochemical relapse, and patients carrying the GSTP1 c.313 GG genotype were at higher risk of recurrence. Two other studies that investigated this polymorphism did not find statistically significant associations with PCa recurrence. 10, 11 These discrepancies might be partially due to the fact that the latter studies included Caucasian men, whereas our patients are Hispanic. Our results showed that the genotype frequencies among these Argentine men are more similar to Caucasians from Spain and Italy than to US Hispanics and Hispanics from Chile, in agreement with the large proportion of Spanish and Italian ancestry among Argentines from Buenos Aires, from where patients in our study came from. However, Argentines, as all Hispanics, have an admixed genetic background that includes Europeans, Amerindians and African ancestries. 15 Our study did not include genetic ancestry estimation using ancestry informative markers; therefore, we were unable to adjust for potential confounding by population admixture.
We also found that patients with more than two risk alleles of the combined GSTT1, GSTM1 and GSTP1 polymorphisms were at higher risk for developing a biochemical relapse. These results agree with the results reported by Nock et al. 10 who found that Caucasian men with more than two GST risk alleles and more aggressive tumors (Gleason score X8 or pT stage X3a) had an increased risk for recurrence.
The primary strength of our study is the inclusion of patients who underwent RRP without neoadjuvant therapy, which avoided the potential confounding effect of other types of treatment. Key Figure 3 . Biochemical relapse-free survival analysis (BRFS) by glutathione-S-transferase (GST) genotype. To study BRFS, time was calculated from date of radical retropubic prostatectomy to date of biochemical relapse or last follow-up. The figure depicts the Kaplan-Meier survival analysis by genotypes: (a) GSTT1 (log-rank P ¼ 0.1480), (b) GSTM1 (log-rank P ¼ 0.4901), (c) GSTP1 additive model (log-rank Po0.010), (d) GSTP1 recessive model (log-rank P ¼ 0.003) and (e) GST combined genotype using the GSTP1 recessive model (log-rank P ¼ 0.010).
limitations are the modest number of patients included, the possible long-survivorship bias due to the retrospective study design, and that eight men were only followed for periods shorter than the median time to relapse (36 months) and might develop a biochemical relapse later on. Moreover, we did not evaluate GSTP1 promoter methylation, which is a frequent epigenetic event in PCa and is suggested to be a predictor for PCa recurrence. 18 It was reported that serum GSTP1 hypermethylation was detected in 15% of the patients who recurred. 18 Therefore, it might be challenging to clearly determine the role of the GSTP1 SNP in biochemical relapse without considering methylation status.
GSTT1 null, GSTM1 null and GSTP1 c.313 A4G polymorphisms might be relevant predictors of biochemical relapse of PCa in the Argentine population. However, these results need to be validated with a larger patient cohort. Our results give support to the inclusion of molecular markers into clinical practice in an effort to better classify men with localized PCa according to their risk of progression, which may lead to tailored post-surgery therapies and, therefore, will avoid overtreatment. 
